Mean values of leukocyte differential counts, CRP and NLR in study subjects.

<p>Values are given as mean ± standard deviation or n (%) unless otherwise specified.</p><p>MIR, maternal inflammatory response; FIR, fetal inflammatory response; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.</p>a<p>Comparison between groups with no placental inflammation and MIR;</p>b<p>Comparison between groups with MIR and FIR;</p>c<p>Comparison between groups with no placental inflammation and FIR;</p>d<p>Comparison among groups with no placental inflammation, MIR and FIR.</p><p>Mean values of leukocyte differential counts, CRP and NLR in study subjects.</p

Kaplan-Meier overall survival of admission-to-delivery intervals according to C-reactive protein (CRP) levels and neutrophil to lymphocyte (NLR) status.

<p>Kaplan-Meier overall survival of admission-to-delivery intervals according to C-reactive protein (CRP) levels and neutrophil to lymphocyte (NLR) status.</p

Kaplan-Meier overall survival of admission-to-delivery intervals according to C-reactive protein (CRP)

<p>(a) and neutrophil to lymphocyte ratio (NLR) (b). CRP-positive (≥7.46), NLR-positive (≥6.48), dotted line; CRP-negative (<7.46), NLR-negative (<6.48), broken line.</p

Diagnostic indices of leukocyte differential counts, CRP and NLR in study subjects.

<p>AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.</p><p>Diagnostic indices of leukocyte differential counts, CRP and NLR in study subjects.</p

Stability of E1-reporter monobodies in serum.

<p>(A) Luciferase activity measurement of E1-Rluc8. The proteins were incubated with mouse serum for the indicated times. The light emitted from E1-Rluc8 was measured using a luminometer after treatment with coelenterazine. E1-Rluc8 incubated in boiled serum was used as a control. (B) Fluorescence activity measurement of E1-EGFP. The fluorescence emitted by E1-EGFP was measured using a fluorometer.</p

<i>In vivo</i> imaging analysis with the E1-reporter monobody in tumor xenograft mice.

<p>(A) Measurement of luminescence in mice injected with different concentrations of E1-Rluc8. PC3 and HeLa cells were transplanted into 6-week-old Balb/c nude mice via subcutaneous injection (n = 3). After tumor formation, the indicated amounts of E1-Rluc8 and coelenterazine were intravenously injected via the tail vein, and luminescence images were acquired at the indicated times with the NightOWL <i>in vivo</i> imaging system (left). The luminescence intensities measured in tumor areas at 6 h were graphed (right). (B) Luminescence maintenance in mice injected with E1-Rluc8 for 24 h. E1-Rluc8 (60 μg) and coelenterazine were intravenously injected via the tail vein into PC3 tumor mice (n = 5), and luminescence images were obtained at the indicated times (left). The luminescence intensities in tumor tissues were measured with the NightOWL <i>in vivo</i> imaging system and graphed (right). (C) Detection of the remaining E1-Rluc8 in PC3 tumor tissues. Tumor tissues were collected at the indicated times from mice injected with E1-Rluc8 and stained with FITC-conjugated anti-6×His antibodies (green). hEphA2 was stained with mouse anti-hEphA2 antibody and Alexa 555-conjugated anti-mouse IgG (red). Cell nuclei were stained with DAPI (blue). Scale bar, 10 μm.</p

hEphA2 expression in tumor cells.

<p>(A) Western blot analysis of hEphA2. Lysates of PC3 and HeLa cells (8 × 10⁵) were separated by SDS-PAGE and transferred to nylon membranes. Membranes were stained with rabbit anti-hEphA2 or β-actin antibodies. (B) Flow cytometric analysis of cells. Cells (5 × 10⁵) were stained with mouse anti-hEphA2 and Alexa 488-conjugated anti-mouse IgG antibodies (anti-hEphA2), and fluorescence was measured by flow cytometry. Unstained cells or cells stained with Alexa 488-conjugated anti-mouse IgG antibody (2^nd Ab) alone were used as controls.</p

E1-reporter monobody cell binding.

<p>(A) Flow cytometric analysis of cells treated with E1-Rluc8 and E1-EGFP. PC3 and HeLa cells (5 × 10⁵) detached from culture plates were treated with E1-Rluc8 and E1-EGFP. The cells treated with E1-Rluc8 were stained with FITC-conjugated mouse anti-6×His antibody. Unstained cells or cells stained with FITC-conjugated secondary antibody (2^nd Ab) alone were used as controls. (B) Fluorescence microscopy images of the cells. PC3 and HeLa cells were stained with mouse anti-hEphA2 antibody and E1-Rluc8, and then detected with Alexa 555-conjugated anti-mouse IgG (red) and FITC-conjugated anti-6×His antibodies (green). Cell nuclei were stained with DAPI (blue). Scale bar, 10 μm. (C) Fluorescence microscopy images of xenograft tumor tissues. PC3 tumor tissues from transplanted nude mice were stained with the antibody combinations used in (B). Scale bar, 10 μm.</p

Location of the p.S288X mutation in <i>EYA4</i> and linked STR markers on chromosome 6q.

<p>The physical map marks the location of 5 microsatellite markers and positions.</p

SNPs of the <i>GRHL2</i> gene identified in this study.

<p>SNPs of the <i>GRHL2</i> gene identified in this study.</p